Celgene buying T-cell tech partner Juno for $9bn

By Dan Stanton

- Last updated on GMT

Gettyimages/CIPhotos
Gettyimages/CIPhotos

Related tags: T cell receptor

Celgene will add chimeric antigen receptor (CAR) and T-cell receptor (TCR) technologies through the acquisition of its immune-oncology partner Juno Therapeutics.

Celgene confirmed speculation it was buying Juno yesterday by announcing the two firms had come to an agreement to merge.

New Jersey-based Celgene will pay around $9bn (€7.4bn) for the firm, net of the nine million Juno shares it already owns in the company, valued at approximately $800m.

The firms have been working together since July 2015​ when they entered into a 10-year immunotherapy partnership, valued at around $1bn.

Full ownership will place Celgene “at the forefront of future advances in the science of cellular immunotherapy,”​ the company said.

Along with autologous CAR T-cell pipeline boosts in the way of early-phase candidates JCAR017 for non-Hodgkin lymphoma (NHL) and JCARH125 for multiple myeloma, Celgene will add Juno’s scientific platform and scalable manufacturing technologies to its cell therapy capabilities.

This includes cell selection and activation capabilities, and manufacturing automation technologies Juno picked up from German biotech Stage Cell Therapeutics GmbH ​in 2015.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us

Products

View more

Webinars